Recruiting

Testing a new injection to help stroke recovery in patients not eligible for standard therapy

Plain-English translation of NCT07396337 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether QHRD106 injection can help people recover from acute ischemic stroke. The study focuses on patients who are not able to receive standard clot-busting treatments within 24 hours of their stroke. Researchers want to find the best dose of this medication and confirm it is safe and effective.

Acute ischemic stroke is a serious condition, but not all patients can receive standard clot-busting therapies due to timing or other medical reasons. This trial is exploring whether this medication could offer a new treatment option for those patients to improve their chances of recovery.

Do you qualify?

You likely qualify if…

you are between 18 and 80 years old
you have been diagnosed with acute ischemic stroke
you cannot receive or have not received standard intravenous clot-busting therapy within 24 hours of stroke onset, and you can receive the first treatment dose within 24 hours of symptom onset
your stroke severity (measured by a standard neurological scale) falls within a specific range that shows meaningful arm or leg weakness
you were independent or nearly independent in daily activities before your stroke

You likely don't qualify if…

you have any bleeding in the brain or a history of bleeding disorders
you have known allergies to the study medication, imaging contrast dyes, pig-derived products, or have had severe allergic reactions to multiple medications
you have a condition called alpha-1 antitrypsin deficiency
you have already received other neuroprotective medications (a specific list of drugs commonly used in stroke care) since your stroke began
you have severe high blood pressure that remains uncontrolled even with medication, or you are planning to have or have already undergone an endovascular procedure for your stroke

What participation looks like

You would receive three injections of either the new medication or a placebo, given one week apart, starting within 24 hours of your stroke. Over the course of the study (several weeks), you would visit the clinic for injections and assessments to measure your recovery and check for any side effects. The study uses a blind design, meaning neither you nor the research team will know which treatment you receive until the trial is complete.

AI-generated summary from trial data · Jul 1, 2026 · Not medical advice

Trial locations(1 site)

China

Nanjing Drum Tower Hospital, Nanjing, Jiangsu

Testing a new injection to help stroke recovery in patients not eligible for standard therapy

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)

Key details

Contact the research team directly

Interested in joining?